EUVIMEDEUVIMED entdecken
LeitlinieOpen Access

GLP ‐1 Receptor Agonist Therapy for Obesity Under Japan's Optimal Use Guideline: A Prospective Real‐World Study of Lifestyle Pre‐Treatment, Time‐Limited Treatment Cap, and Post‐Cessation Regain

Susumu Inamine iD, Yasunori Uesato iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71190 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Susumu Inamine und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Metabolic and Bariatric Surgery, Ohama Daiichi Hospital, Naha, Okinawa, Japan. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Glucagon-Like Peptides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Japan's optimal use guideline restricts insurance‐reimbursed GLP‐1 receptor agonist (GLP‐1 RA) therapy for obesity to patients completing a mandatory 6‐month lifestyle intervention, caps treatment at 68 weeks (semaglutide 2.4 mg) or 72 weeks (tirzepatide), and mandates subsequent washout. We evaluated the clinical implications of this regulated program in a real‐world cohort of patients with obesity treated with semaglutide or tirzepatide, with particular attention to pre‐treatment weight change during the mandated lifestyle phase, on‐treatment response, and post‐cessation weight regain. Materials and Methods We prospectively followed 104 patients with obesity without type 2 diabetes (45 primary, 59 post‐metabolic/bariatric‐surgery rescue) treated with semaglutide ( n = 43) or tirzepatide ( n = 61) under Japan's optimal use guideline. Both cohorts qualified for GLP‐1 RA under the same insurance eligibility criteria (BMI ≥ 27 kg/m 2 with obesity‐related comorbidities). Body weight was recorded bimonthly from 6 months before drug initiation through the post‐cessation washout phase. Outcomes included percent body weight change from baseline and rates of weight loss and regain across phases.

Results

During the mandated lifestyle phase, the rescue cohort gained weight (+2.28 ± 4.16 kg; 69% gained weight), while the primary cohort remained essentially stable (−0.65 ± 5.51 kg; p = 0.004). Once GLP‐1 RA was initiated, % body weight change trajectories were comparable between cohorts from month 4 onward (month 6: −11.8% vs. −10.8%, p = 0.57). Aggregate % body weight change reached a partial plateau by months 10–14 (−16.3%, −16.1%, −15.5%) and was −16.0% at the treatment endpoint (month 16, n = 30, all semaglutide‐treated). After mandated cessation, 95% (21/22) of patients regained weight by 2 months, and 83% (10/12) by 6 months. Indexed to month −6, mean change reverted from −14.4% at month 16 to −7.0% at month 22, indicating substantial loss of achieved treatment benefit.

Conclusions

Under Japan's current regulatory framework, GLP‐1 RAs produced comparable weight loss in primary and rescue cohorts sharing the same eligibility criteria. Phase‐specific observations—pre‐treatment weight gain in the rescue cohort and achieved treatment effect that reverted rapidly after mandated cessation—provide a real‐world basis for examining whether mandated treatment cessation is compatible with the chronic nature of obesity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsObesityGlucagon-Like PeptidesHumansSemaglutideFemaleJapanMaleProspective StudiesTirzepatideMiddle AgedWeight GainLife StylePractice Guidelines as TopicAdultWeight LossTreatment Outcome

Stichwörter der Autor:innen

GLP‐1 receptor agonisthealthcare policyobesitysemaglutidetirzepatideweight regain

Substanzen

SemaglutideGlucagon-Like Peptide-1 Receptor AgonistsTirzepatideGlucagon-Like Peptides

Autor:innen und Institutionen

  • Center for Metabolic and Bariatric Surgery, Ohama Daiichi Hospital, Naha, Okinawa, Japan.

ORCID-Profile: Susumu Inamine, Yasunori Uesato

Zitieren

APA

Inamine, S., & Uesato, Y. (2026). GLP ‐1 Receptor Agonist Therapy for Obesity Under Japan's Optimal Use Guideline: A Prospective Real‐World Study of Lifestyle Pre‐Treatment, Time‐Limited Treatment Cap, and Post‐Cessation Regain. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71190

Vancouver

Inamine S, Uesato Y. GLP ‐1 Receptor Agonist Therapy for Obesity Under Japan's Optimal Use Guideline: A Prospective Real‐World Study of Lifestyle Pre‐Treatment, Time‐Limited Treatment Cap, and Post‐Cessation Regain. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71190

BibTeX
@article{Inamine2026,
  author = {Inamine, Susumu and Uesato, Yasunori},
  title = {GLP ‐1 Receptor Agonist Therapy for Obesity Under Japan's Optimal Use Guideline: A Prospective Real‐World Study of Lifestyle Pre‐Treatment, Time‐Limited Treatment Cap, and Post‐Cessation Regain},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71190}
}
Kostenlos starten →